There was no significant difference in risk for retinopathy (370/13680 versus 359/13709, OR: 1.15, 95% CI: 0.83 to 1.60, P = 0.394) between the use of GLP1R agonists and placebo (Fig. 6). The gene discussed is GLP1R; the disease is retinal disorder.